Azole resistance in Aspergillus: Global status in Europe and Asia

Annals of the New York Academy of Sciences

Volumn 1272, Issue 1, 2012, Pages 9-14

  Arikan Akdagli, Sevtap ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antifungal susceptibility testing; Aspergillus; Azole; Resistance

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASIA; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; EUROPE; FUNGUS TRANSMISSION; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; NONHUMAN;

EID: 84870936086     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06815.x     Document Type: Article

References (32)

1. Denning, D.W., K. Venkateswarlu, K.L. Oakley, et al 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother 41: 1364-1368.
2. Denning, D.W., S.A. Radford, K.L. Oakley, et al 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40: 401-414.
3. Verweij, P.E., S.J. Howard, W.J.G. Melchers & D.W. Denning 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updates 12: 141-147.
4. CLSI. 2008. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard 2nd ed. CLSI Document M38-A2. Clinical and Laboratory Standards Institute. Wayne, PA
5. Espinel-Ingroff, A., D.J. Diekema, A. Fothergill, et al 2010. Wild-type MIC distributions and epidemiological cut-off values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48: 3251-3257.
6. Itraconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0. 11 January 2012.
7. Posaconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0. 17 January 2012.
8. Voriconazole. Rationale for the EUCAST clinical breakpoints, version 1.0. March 2012.
9. EUCAST Antifungal Breakpoints: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Antifungal_breakpoints_v_4.1.pdf. Accessed October 29, 2012.
10. EUCAST Comments on proposed itraconazole breakpoints for Aspergillus spp. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/EUCAST_Itra_consultation_comments_and_responses_f.pdf. Accessed January 11, 2012
11. Denning, D.W. & D.S. Perlin 2011. Azole resistance in Aspergillus: a growing public health menace. Future. Microbiol. 6: 1229-1232.
12. Pfaller, M., L. Boyken, R. Hollis, J. Kroeger, et al 2011. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. J. Clin. Microbiol. 49: 1110-1112.
13. Arikan, S., B. Sancak, S. Alp, et al 2008. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med. Mycol. 46: 567-573.
14. Verweij, P.E., D.T. Te Dorsthorst, A.J. Rijs, et al 2002. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J. Clin. Microbiol. 40: 2648-2650.
15. Snelders, E., H.A. van der Lee, J. Kuijpers, et al 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5: e219.
16. Van der Linden, J.W., E. Snelders, G.A. Kampinga, et al 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerging Infect. Dis. 17: 1846-1854.
17. Howard, S., D. Cerar, M.J. Anderson, et al 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis 15: 1068-1076.
18. Tashiro, M., K. Izumikawa, A. Minematsu, et al 2012. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob. Agents Chemother. 56: 584-587.
19. Chowdhary, A., S. Kathuria, H.S. Randhawa, et al 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67: 362-366.
20. Van der Linden, J., M.C. Arendrup, P.E. Verweij, SCARE Network. 2011. Prospective international surveillance of azole resistance in Aspergillus fumigatus. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, Chicago USA, M-490.
21. Pfaller, M.A., S.A. Messer, L. Boyken, et al 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol 46: 2568-2572.
22. Lockhart, S.R., J.P. Frade, K.A. Etienne, et al 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS Global Surveillance Study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55: 4465-4468.
23. Alanio, A., E. Sitterlé, M. Liance, et al 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother 66: 371-374.
24. Burgel, P.R., M.T. Baixench, M. Amsellem, et al 2012. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56: 869-874.
25. Mortensen, K.L., R.H. Jensen, H.K. Johansen, et al 2011. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 49: 2243-2251.
26. Denning, D.W., S. Park, C. Lass-Florl, et al 2011. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52: 1123-1129.
27. Bueid, A., S.J. Howard, C.B. Moore, et al 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65: 2116-2118.
28. Guinea, J., S. Recio, T. Peláez, et al 2008. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob. Agents Chemother 52: 3444-3446.
29. Pfaller, M., L. Boyken, R. Hollis, et al 2011. Use of epidemiological cut-off values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49: 586-590.
30. Howard, S.J., E. Harrison, P. Bowyer, et al 2011. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob. Agents Chemother. 55: 4802-4809.
31. Snelders, E., R.A. Huis In 't Veld, A.J. Rijs, et al 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75: 4053-4057.
32. Mortensen, K.L., E. Mellado, C. Lass-Flörl, et al 2010. Environmental study of azole-resistant Aspergillus fumigatus and other Aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54: 4545-4549.